“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
With 4,000 studies and 2,000,000 patients enrolled in 90 countries, Castor will use the investment to invest more in data-driven, patient-centered clinical trials.
HOBOKEN, N.J., August 19, 2020 / PRNewswire / – Beaver, a leading provider of clinical trial generation that automates the study process, announced today that it has raised $12 million in funds. The tour was conducted through Two Sigma Ventures with the participation of Hambrecht Ducera Growth Ventures and the existing investor INKEF Capital.
Beaver is a leading cloud-based clinical knowledge platform that simplifies the clinical trial process, from recruitment to analysis, for people around the world. It is used through more than 50,000 users in the Academy and Array advertising driving more than 4,000 studies with more than 2,000,000 patients enrolled in 90 countries. 192 medical device corporations, biotechnological and pharmaceutical corporations and contract organizations (CROs) use Castor’s platform.
Beaver has caused its platform to miss out on all non-profit COVID-19 studios starting in February. They are one of the only suppliers that can allow large-scale decentralized trials to boost the paintings of scholars seeking the disease. More than two hundred COVID-19 projects in 33 countries are recently being implemented on the platform, adding the World Health Organization’s Global Solidarity Trial. Through its platform, more than one million COVID-19 knowledge problems have been captured and 50 COVID-19 projects are committed to making their knowledge reusable and available to others, so that the world can work well to prevent the disease.
“There are three key demanding situations in the clinical trial space: making studies more patient-centered, maximizing the effect on knowledge on human life, and a greater gathering of the desires of undersattented communities,” said Derk Arts, MD, PhD. Array CEO and founder of Castor. “With this new investment, we will be able to make significant progress in all 3 spaces by providing an available and easy-to-use generation that can help remote testing, while ensuring machine-readable results for test automation and knowledge reuse. For the next 18 months, we aim to help our clients with the recruitment of patients and artificially controlled weapons, through greater use of their knowledge industries.”
Beaver will use this new investment to further strengthen its support for patient-centered remote trials and to enable customers to maximize the price of existing and newly generated knowledge in the clinical trial process.
“We believe that the life sciences industry lacks a comprehensive and scalable solution to recruit applicants for clinical trials, administer the study procedure, and leverage the wealth of knowledge produced through these clinical trials to generate medical advances,” said Villi Iltchev, spouse of Two Sigma Ventures. “Castor’s generation and team have the ability to meet all those needs, as evidenced by the call of visitors and the ability to penetrate new segments. We are convinced that your vision of enabling AI and automation in clinical trials will temporarily replace the face of the studies. Array “
About Beaver
Headquartered in the United States and the Netherlands, Castor is a foreign health care generation company founded by CHIEF Executive Derk Arts, MD, PhD. Its cloud-based clinical knowledge platform simplifies the clinical trial process, from recruitment to analysis, for researchers around the world.
More than 50,000 scholars in 90 countries are employing Castor to bring their studies to life. The Castor Platform has supported more than 4,000 advertising and educational studies covering a wide variety of healing areas, adding diabetes, cardiovascular disease, rare diseases, infectious diseases and oncology. The platform’s studies generate gigantic amounts of knowledge from classic and remote trials, and Castor has recently reached milestones of 180,000,000 knowledge problems and 2,000,000 registered patients. Castor’s purpose is to make knowledge of global studies reusable, enable AI-based clinical trials, and ultimately create a long-term in which they maximize the effect of knowledge through reuse.
In 2018, Castor raised $6.25 million from investor INKEF Capital in Europe.
Karolina Kmiecik [email protected] Press Contacts
John Ambrose [email protected]
View the content to download multimedia: http://www.prnewswire.com/news-releases/castor-raises-a-12m-series-a-to-fother-their-support-for-covid-19-research-through- trial-clinical-and-data-automation-301114418.html
SOURCE Beaver